Stock Watch: When Development Goes Too Far

Beware R&D Organizations With Unfettered Access To Clinical Trial Budgets

R&D managers can sometimes drive a drug’s development despite evidence of its unviability. This has recently resulted in a scramble to adjust in-progress trial protocol and post-approval cost-effectiveness concerns.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Two of the most formative experiences I gained working as the commercial person within pharmaceutical development teams involved the inability to predict either the absence of patients or the absence of a viable market for products under development.

As the largest items of biotech and pharma companies’ operational expenditure, clinical trials are subject to rigorous planning and monitoring....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Stock Watch

More from Business